Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NK cell immunotherapy for breast cancer
IRCT20160809029275N6Phase 2Recruiting
- Sponsor
- Pooya Gostar Royana
- Start
- Jun 2025
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label trial of Natural Killer Cells, aldesleukin and recombinant human interleukin-15 in breast cancer (4 arms), sponsored by Pooya Gostar Royana. Primary endpoints: Clinical safety monitoring, CBC and CRP and 2 more. Started Jun 2025; status: recruiting.
02
Drugs
Natural Killer Cellsaldesleukinrecombinant human interleukin-15
03
Conditions
breast cancer
Beyond the preview
Go deeper on IRCT20160809029275N6.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20160809029275N6.